Fabry Disease Market Outlook: 6 Upcoming Therapies Set to Influence the Future Market Landscape | DelveInsight
The emerging Fabry disease market landscape holds a diverse range of therapeutic alternatives for treatment, including Venglustat (Sanofi Genzyme), Lucerastat (Idorsia Pharmaceuticals), Isaralgagene civaparvovec (ST-920; Sangamo Therapeutics), AMT-191 (UniQure), AL1211 (AceLink...
Covered in this story
What has happened since
- Sanofi is up 0.7% since this was published, 19 days ago.
- American Tower is up 14.0% since this was published, 19 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $SAN.PA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Sanofi →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.